Skip to main content

iABC Programme

Objective


Cystic Fibrosis (CF) is a common fatal inherited disease with a frequency of 1 in 2500 live births, affecting approximately 36,000 (0.737/10,000) people in the EU. Chronic bacterial pulmonary infection leading to an irreversible decline in lung structure and function is the main cause of mortality and morbidity in patients with CF, with more than 95% of deaths due to respiratory failure. Pseudomonas aeruginosa (Pa) is the most frequently isolated pathogen, chronically infecting up to 80% of adult patients. When this occurs patients require lifelong inhaled antibiotic therapy, which although onerous to take, has been fundamental in increasing life expectancy by suppressing infection, reducing exacerbations and preserving lung function in CF patients chronically infected with Pa. Studies employing enhanced culture techniques and culture-independent molecular approaches have recently shown that the lungs of CF patients harbour diverse polymicrobial communities, the “microbiome”. Other Gram-negative non-fermenting bacteria (GNnF), including Stenotrophomonas maltophilia and bacteria from the genera Burkholderia, Achromobacter, Acinetobacter, Ralstonia and Pandoraea may be present and contribute to disease. Moreover, Burkholderia cenocepacia is associated with rapid deterioration of lung function and poor clinical outcome.

Estimates for the prevalence of non-CF bronchiectasis (BE) range from 4 per 100 000 in young adults to nearly 300 per 100,000 in persons 75 years and older in developed countries. The number of adults is increasing significantly and the forecast is that the number of adults with CF will increase by 100% between 2010 and 2025. These individuals will mostly have chronic infection with Pa.

Individuals with BE have chronic cough and sputum production and frequent respiratory infections which lead to impaired lung function and health-related quality of life. Chronic infection with Pa affects 12–27% of adults with BE and is associated with an increased exacerbation frequency, an accelerated decline in lung function, hospital admissions and increased mortality. There is a direct relationship between bacterial load, airway inflammation and risk of exacerbation supporting the use of long-term administration of inhaled antibiotics in BE.

Currently, a limited number of inhaled antimicrobials are available for use in CF with no antibiotics approved to treat lung infection in patients with BE. As median predicted survival of CF birth cohorts is now greater than 40 years, adherence to consensus treatment guidelines requires that chronically infected patients are treated for decades with inhaled antimicrobials. Furthermore, bacteria causing respiratory infection are becoming progressively more resistant to conventional antibiotics with up to 45% of CF patients colonised with multidrug resistant (MDR) pathogens. New antibiotics with activity against such respiratory pathogens are urgently needed.

The iABC-consortium (inhaled Antibiotics in Bronchiectasis and Cystic fibrosis) brings together world leading collaborative researchers to develop new antibiotic treatment options for people with CF and BE by sharing expertise and resources. It involves about 20 public partners and 2 pharmaceutical companies in 6 countries and 4 pan-European networks: ECFS-CTN, CLIN-Net, LAB-Net and EMBARC. These networks inclide almost all European countries and will be used to recruit centres for the clinical trials. These groups combine experience and proven expertise and success in microbiology, antibiotic development, clinical trials, endpoints and patient registries. Their existing infrastructure provides an excellent basis for the successful achievement of the objectives of ND4BB Topic 7.

The iABC consortium will build on and add to existing research networks and infrastructures within the IMI ND4BB-program, thereby strengthening these networks for future research programs. Considerable overlap already exists between ECFS-CTN

Call for proposal

IMI-JU-11-2013
See other projects for this call

Funding Scheme

JTI-CP-IMI - Joint Technology Initiatives - Collaborative Project (IMI)

Coordinator

NOVARTIS PHARMA AG
Address
Lichtstrasse 35
4056 Basel
Switzerland
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Principal investigator
Gerhild Angyalosi (Dr.)
Administrative Contact
Vincent Malaterre (Dr.)

Participants (21)

THE QUEEN'S UNIVERSITY OF BELFAST
United Kingdom
EU contribution
€ 18 327 968
Address
University Road Lanyon Building
BT7 1NN Belfast
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Sinead Cahill (Mrs)
Basilea Pharmaceutica Ltd

Participation ended

Switzerland
Address
Grenzacherstrasse 487
4058 Basel
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Mark Jones (Dr)
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Netherlands
EU contribution
€ 1 240 553
Address
Heidelberglaan 100
3584 CX Utrecht
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Wouter Bongers (Mr)
BELFAST HEALTH AND SOCIAL CARE TRUST
United Kingdom
EU contribution
€ 85 138
Address
Lisburn Road Belfast City Hospital A Floor
BT9 7AS Belfast
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Administrative Contact
Sarah Kathleen O'Brien (Senior Finance Manager Income and Research)
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.

Participation ended

Germany
EU contribution
€ 24 944
Address
Hansastrasse 27C
80686 Munchen
Activity type
Research Organisations
Administrative Contact
Andrea Zeumann (Ms)
RIJKSUNIVERSITEIT GRONINGEN
Netherlands
EU contribution
€ 414 087
Address
Broerstraat 5
9712CP Groningen
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Dick Veldhuis (Dr)
SERVICIO MADRILENO DE SALUD
Spain
EU contribution
€ 337 001
Address
Plaza Carlos Trias Bertran 7
28020 Madrid
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Administrative Contact
JOSÉ IGNACIO FLORES NICOLÁS (MR.)
UNIVERSITAIR ZIEKENHUIS ANTWERPEN
Belgium
EU contribution
€ 1 095 505
Address
Wilrijkstraat 10
2650 Edegem
Activity type
Research Organisations
Administrative Contact
Daisy Van Mieghem (Accountant)
UNIVERSITY OF DUNDEE
United Kingdom
EU contribution
€ 1 547 383
Address
Nethergate
DD1 4HN Dundee
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Jim McGregor (Mr)
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
Address
Rue De Tolbiac 101
75654 Paris
Activity type
Research Organisations
Administrative Contact
SANDRA BARBARY (MRS)
UNIVERSITA DEGLI STUDI DI MILANO
Italy
EU contribution
€ 100 284
Address
Via Festa Del Perdono 7
20122 Milano
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Antonia Maria Giofrè (DOTT)
HOSPICES CIVILS DE LYON
France
EU contribution
€ 9 057
Address
Quai Des Celestins 3
69002 Lyon
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Administrative Contact
Delphine MAURICE (Mrs)
MEDIZINISCHE HOCHSCHULE HANNOVER
Germany
EU contribution
€ 156 993
Address
Carl-neuberg-strasse 1
30625 Hannover
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Simone Hess (Dr)
UNIVERSITEIT ANTWERPEN
Belgium
Address
Prinsstraat 13
2000 Antwerpen
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Anne Adams (Mrs.)
THE UNIVERSITY OF EDINBURGH
United Kingdom
EU contribution
€ 106 444
Address
Old College, South Bridge
EH8 9YL Edinburgh
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Angela Noble (Ms)
ROYAL BROMPTON AND HAREFIELD NATIONAL HEALTH SERVICE TRUST
United Kingdom
EU contribution
€ 123 011
Address
Sydney Street
SW3 6NP London
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Laura Henderson (Ms)
FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA

Participation ended

Spain
EU contribution
€ 10 700
Address
Carrer Rossello 149
08036 Barcelona
Activity type
Research Organisations
Administrative Contact
Rosa Vilavella (Mrs.)
PAPWORTH HOSPITAL NHS FOUNDATION TRUST
United Kingdom
EU contribution
€ 152 519
Address
Papworth Everard
CB23 3RE Cambridge
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Administrative Contact
Sophie Jackson (Mrs)
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Netherlands
EU contribution
€ 563 022
Address
Dr Molewaterplein 40
3015 GD Rotterdam
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Ellen Schenk (Dr.)
FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA
Spain
EU contribution
€ 37 000
Address
Passeig Vall D Hebron 119-129 Edificio De Recerca
08035 Barcelona
Activity type
Research Organisations
Administrative Contact
Estel Gil (Mrs)
Polyphor AG
Switzerland
Address
Hegenheimermattweg
4123 Allschwil
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Helmut Kessmann (Dr)